Decision ruleHaematology

Nordic model for erythropoietin ± G-CSF response in MDS

Predicts the probability of erythroid response to erythropoietin plus G-CSF in the anaemia of myelodysplastic syndromes.

Updated 30 October 2026

When to use it

Lower-risk MDS with symptomatic anaemia, before starting an erythropoiesis-stimulating agent.

What it needs

  • Serum EPOOptions: ≤ 500 U/L · > 500 U/L
  • Red cell transfusion needOptions: < 2 units/month · ≥ 2 units/month

The points for each answer and the automatic total are in the app.

How to interpret it

Unfavourable factors
ResultInterpretation
≤ 0High probability of response (≈ 61 % in validation)
1Intermediate probability of response (≈ 14 % in validation)
≥ 2Low probability of response: treatment not recommended

Practical tip

The two predictors are serum EPO (> 500 U/L) and transfusion need (≥ 2 red cell units per month).

3 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top